APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaccine (Include COVID-19)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Vaccine (Include COVID-19) Market Analysis and Forecast 2026-2032

Report ID 174044840221 December 2025208 pages

Choose your research edition.

Industry ResearchVaccine (Include COVID-19) Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine (Include COVID-19) Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Vaccine (Include COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine (Include COVID-19) Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine (Include COVID-19) Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Vaccine (Include COVID-19) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Vaccine (Include COVID-19) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Vaccine (Include COVID-19) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Vaccine (Include COVID-19) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Vaccine (Include COVID-19) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Vaccine (Include COVID-19) include Sanofi, Merck, Pfizer, GSK, AstraZeneca, Zhejiang Pukang, Walvax Biotechnology, Viatris and Sinovac, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Vaccine (Include COVID-19), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Vaccine (Include COVID-19), also provides the revenue of main regions and countries. Of the upcoming market potential for Vaccine (Include COVID-19), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vaccine (Include COVID-19) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Vaccine (Include COVID-19) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Vaccine (Include COVID-19) revenue, projected growth trends, production technology, application and end-user industry.

Vaccine (Include COVID-19) Segment by Company

Sanofi

Merck

Pfizer

GSK

AstraZeneca

Zhejiang Pukang

Walvax Biotechnology

Viatris

Sinovac

Sinovac

Serum Institute

Panacea Biotec Ltd

LG Life Sciences

KM Biologics

Hualan Bio

Halfkin Bio-Pharmaceuticals

CSL

Changchun Institute of Biological

Bio-Med

Bharat Biotech

Vaccine (Include COVID-19) Segment by Type

Inactivated Vaccine

Attenuated Vaccine

mRNA

Other

Vaccine (Include COVID-19) Segment by Application

Public

Private

Vaccine (Include COVID-19) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine (Include COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine (Include COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine (Include COVID-19).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Vaccine (Include COVID-19) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Vaccine (Include COVID-19) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine (Include COVID-19) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vaccine (Include COVID-19) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Inactivated Vaccine Major Player Table 3. Attenuated Vaccine Major Player Table 4. mRNA Major Player Table 5. Other Major Player Table 6. Global Vaccine (Include COVID-19) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Public Major Player Table 8. Private Major Player Table 9. Vaccine (Include COVID-19) Industry Trends Table 10. Vaccine (Include COVID-19) Industry Drivers Table 11. Vaccine (Include COVID-19) Industry Opportunities and Challenges Table 12. Vaccine (Include COVID-19) Industry Restraints Table 13. Global Vaccine (Include COVID-19) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Vaccine (Include COVID-19) Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Vaccine (Include COVID-19) Market Share by Region (2021-2026) Table 16. Global Vaccine (Include COVID-19) Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Vaccine (Include COVID-19) Market Share by Region (2027-2032) Table 18. Global Vaccine (Include COVID-19) Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Vaccine (Include COVID-19) Revenue Market Share by Players (2021-2026) Table 20. Global Vaccine (Include COVID-19) Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Vaccine (Include COVID-19) Key Players Headquarters & Area Served Table 22. Global Vaccine (Include COVID-19) Players, Product Type & Application Table 23. Global Vaccine (Include COVID-19) Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Vaccine (Include COVID-19) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Vaccine (Include COVID-19) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Vaccine (Include COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Vaccine (Include COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Vaccine (Include COVID-19) Revenue Market Share by Type (2021-2026) Table 30. Global Vaccine (Include COVID-19) Revenue Market Share by Type (2027-2032) Table 31. Global Vaccine (Include COVID-19) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Vaccine (Include COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Vaccine (Include COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Vaccine (Include COVID-19) Revenue Market Share by Application (2021-2026) Table 35. Global Vaccine (Include COVID-19) Revenue Market Share by Application (2027-2032) Table 36. Sanofi Company Information Table 37. Sanofi Business Overview Table 38. Sanofi Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi Vaccine (Include COVID-19) Product Portfolio Table 40. Sanofi Recent Development Table 41. Merck Company Information Table 42. Merck Business Overview Table 43. Merck Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Merck Vaccine (Include COVID-19) Product Portfolio Table 45. Merck Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Pfizer Vaccine (Include COVID-19) Product Portfolio Table 50. Pfizer Recent Development Table 51. GSK Company Information Table 52. GSK Business Overview Table 53. GSK Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. GSK Vaccine (Include COVID-19) Product Portfolio Table 55. GSK Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AstraZeneca Vaccine (Include COVID-19) Product Portfolio Table 60. AstraZeneca Recent Development Table 61. Zhejiang Pukang Company Information Table 62. Zhejiang Pukang Business Overview Table 63. Zhejiang Pukang Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Zhejiang Pukang Vaccine (Include COVID-19) Product Portfolio Table 65. Zhejiang Pukang Recent Development Table 66. Walvax Biotechnology Company Information Table 67. Walvax Biotechnology Business Overview Table 68. Walvax Biotechnology Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Walvax Biotechnology Vaccine (Include COVID-19) Product Portfolio Table 70. Walvax Biotechnology Recent Development Table 71. Viatris Company Information Table 72. Viatris Business Overview Table 73. Viatris Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Viatris Vaccine (Include COVID-19) Product Portfolio Table 75. Viatris Recent Development Table 76. Sinovac Company Information Table 77. Sinovac Business Overview Table 78. Sinovac Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Sinovac Vaccine (Include COVID-19) Product Portfolio Table 80. Sinovac Recent Development Table 81. Sinovac Company Information Table 82. Sinovac Business Overview Table 83. Sinovac Vaccine (Include COVID-19) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Sinovac Vaccine (Include COVID-19) Product Portfolio Table 85. Sinovac Recent Development Table 86. Serum Institute Company Information Table 87. Serum Institute Business Overview Table 88. Serum Institute Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Serum Institute Vaccine (Include COVID-19) Product Portfolio Table 90. Serum Institute Recent Development Table 91. Panacea Biotec Ltd Company Information Table 92. Panacea Biotec Ltd Business Overview Table 93. Panacea Biotec Ltd Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Panacea Biotec Ltd Vaccine (Include COVID-19) Product Portfolio Table 95. Panacea Biotec Ltd Recent Development Table 96. LG Life Sciences Company Information Table 97. LG Life Sciences Business Overview Table 98. LG Life Sciences Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. LG Life Sciences Vaccine (Include COVID-19) Product Portfolio Table 100. LG Life Sciences Recent Development Table 101. KM Biologics Company Information Table 102. KM Biologics Business Overview Table 103. KM Biologics Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. KM Biologics Vaccine (Include COVID-19) Product Portfolio Table 105. KM Biologics Recent Development Table 106. Hualan Bio Company Information Table 107. Hualan Bio Business Overview Table 108. Hualan Bio Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Hualan Bio Vaccine (Include COVID-19) Product Portfolio Table 110. Hualan Bio Recent Development Table 111. Halfkin Bio-Pharmaceuticals Company Information Table 112. Halfkin Bio-Pharmaceuticals Business Overview Table 113. Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Product Portfolio Table 115. Halfkin Bio-Pharmaceuticals Recent Development Table 116. CSL Company Information Table 117. CSL Business Overview Table 118. CSL Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. CSL Vaccine (Include COVID-19) Product Portfolio Table 120. CSL Recent Development Table 121. Changchun Institute of Biological Company Information Table 122. Changchun Institute of Biological Business Overview Table 123. Changchun Institute of Biological Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Changchun Institute of Biological Vaccine (Include COVID-19) Product Portfolio Table 125. Changchun Institute of Biological Recent Development Table 126. Bio-Med Company Information Table 127. Bio-Med Business Overview Table 128. Bio-Med Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Bio-Med Vaccine (Include COVID-19) Product Portfolio Table 130. Bio-Med Recent Development Table 131. Bharat Biotech Company Information Table 132. Bharat Biotech Business Overview Table 133. Bharat Biotech Vaccine (Include COVID-19) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Bharat Biotech Vaccine (Include COVID-19) Product Portfolio Table 135. Bharat Biotech Recent Development Table 136. North America Vaccine (Include COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 137. North America Vaccine (Include COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 138. North America Vaccine (Include COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 139. North America Vaccine (Include COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 140. North America Vaccine (Include COVID-19) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. North America Vaccine (Include COVID-19) Revenue by Country (2021-2026) & (US$ Million) Table 142. North America Vaccine (Include COVID-19) Revenue by Country (US$ Million) & (2027-2032) Table 143. Europe Vaccine (Include COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 144. Europe Vaccine (Include COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 145. Europe Vaccine (Include COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 146. Europe Vaccine (Include COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 147. Europe Vaccine (Include COVID-19) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Europe Vaccine (Include COVID-19) Revenue by Country (2021-2026) & (US$ Million) Table 149. Europe Vaccine (Include COVID-19) Revenue by Country (US$ Million) & (2027-2032) Table 150. China Vaccine (Include COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 151. China Vaccine (Include COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 152. China Vaccine (Include COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 153. China Vaccine (Include COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Vaccine (Include COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 155. Asia Vaccine (Include COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 156. Asia Vaccine (Include COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 157. Asia Vaccine (Include COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 158. Asia Vaccine (Include COVID-19) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Asia Vaccine (Include COVID-19) Revenue by Region (US$ Million) & (2021-2026) Table 160. Asia Vaccine (Include COVID-19) Revenue by Region (US$ Million) & (2027-2032) Table 161. SAMEA Vaccine (Include COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 162. SAMEA Vaccine (Include COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 163. SAMEA Vaccine (Include COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 164. SAMEA Vaccine (Include COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 165. SAMEA Vaccine (Include COVID-19) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. SAMEA Vaccine (Include COVID-19) Revenue by Country (2021-2026) & (US$ Million) Table 167. SAMEA Vaccine (Include COVID-19) Revenue by Country (US$ Million) & (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Vaccine (Include COVID-19) Image Figure 2. Global Vaccine (Include COVID-19) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine (Include COVID-19) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Inactivated Vaccine Image Figure 5. Attenuated Vaccine Image Figure 6. mRNA Image Figure 7. Other Image Figure 8. Global Vaccine (Include COVID-19) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Vaccine (Include COVID-19) Market Size Share 2021 VS 2025 VS 2032 Figure 10. Public Image Figure 11. Private Image Figure 12. Global Vaccine (Include COVID-19) Market Size (US$ Million) & (2021-2032) Figure 13. Global Vaccine (Include COVID-19) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Vaccine (Include COVID-19) Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Vaccine (Include COVID-19) Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Vaccine (Include COVID-19) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Vaccine (Include COVID-19) Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Vaccine (Include COVID-19) Revenue Market Share by Type (2021-2032) Figure 20. Global Vaccine (Include COVID-19) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Vaccine (Include COVID-19) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Vaccine (Include COVID-19) Revenue Market Share by Application (2021-2032) Figure 23. North America Vaccine (Include COVID-19) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Vaccine (Include COVID-19) Revenue Share by Type (2021-2032) Figure 25. North America Vaccine (Include COVID-19) Revenue Share by Application (2021-2032) Figure 26. North America Vaccine (Include COVID-19) Revenue Share by Country (2021-2032) Figure 27. United States Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Vaccine (Include COVID-19) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Vaccine (Include COVID-19) Revenue Share by Type (2021-2032) Figure 32. Europe Vaccine (Include COVID-19) Revenue Share by Application (2021-2032) Figure 33. Europe Vaccine (Include COVID-19) Revenue Share by Country (2021-2032) Figure 34. Germany Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Vaccine (Include COVID-19) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Vaccine (Include COVID-19) Revenue Share by Type (2021-2032) Figure 44. China Vaccine (Include COVID-19) Revenue Share by Application (2021-2032) Figure 45. Asia Vaccine (Include COVID-19) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Vaccine (Include COVID-19) Revenue Share by Type (2021-2032) Figure 47. Asia Vaccine (Include COVID-19) Revenue Share by Application (2021-2032) Figure 48. Asia Vaccine (Include COVID-19) Revenue Share by Region (2021-2032) Figure 49. Japan Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Vaccine (Include COVID-19) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Vaccine (Include COVID-19) Revenue Share by Type (2021-2032) Figure 57. SAMEA Vaccine (Include COVID-19) Revenue Share by Application (2021-2032) Figure 58. SAMEA Vaccine (Include COVID-19) Revenue Share by Country (2021-2032) Figure 59. Brazil Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Vaccine (Include COVID-19) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated Vaccine
  • Attenuated Vaccine
  • mRNA
  • Other
Applications
  • Public
  • Private
Companies covered
  • Sanofi
  • Merck
  • Pfizer
  • GSK
  • AstraZeneca
  • Zhejiang Pukang
  • Walvax Biotechnology
  • Viatris
  • Sinovac
  • Sinovac
  • Serum Institute
  • Panacea Biotec Ltd
  • LG Life Sciences
  • KM Biologics
  • Hualan Bio
  • Halfkin Bio-Pharmaceuticals
  • CSL
  • Changchun Institute of Biological
  • Bio-Med
  • Bharat Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Vaccine (Include COVID-19) Market by Type
  3. 1.2.1 Global Vaccine (Include COVID-19) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Inactivated Vaccine
  5. 1.2.3 Attenuated Vaccine
  6. 1.2.4 mRNA
  7. 1.2.5 Other
  8. 1.3 Vaccine (Include COVID-19) Market by Application
  9. 1.3.1 Global Vaccine (Include COVID-19) Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Public
  11. 1.3.3 Private
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Vaccine (Include COVID-19) Market Dynamics
  1. 2.1 Vaccine (Include COVID-19) Industry Trends
  2. 2.2 Vaccine (Include COVID-19) Industry Drivers
  3. 2.3 Vaccine (Include COVID-19) Industry Opportunities and Challenges
  4. 2.4 Vaccine (Include COVID-19) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Vaccine (Include COVID-19) Market Perspective (2021-2032)
  2. 3.2 Global Vaccine (Include COVID-19) Growth Trends by Region
  3. 3.2.1 Global Vaccine (Include COVID-19) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Vaccine (Include COVID-19) Market Size by Region (2021-2026)
  5. 3.2.3 Global Vaccine (Include COVID-19) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Vaccine (Include COVID-19) Revenue by Players
  2. 4.1.1 Global Vaccine (Include COVID-19) Revenue by Players (2021-2026)
  3. 4.1.2 Global Vaccine (Include COVID-19) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Vaccine (Include COVID-19) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Vaccine (Include COVID-19) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Vaccine (Include COVID-19) Key Players Headquarters & Area Served
  7. 4.4 Global Vaccine (Include COVID-19) Players, Product Type & Application
  8. 4.5 Global Vaccine (Include COVID-19) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Vaccine (Include COVID-19) Market CR5 and HHI
  11. 4.6.3 2025 Vaccine (Include COVID-19) Tier 1, Tier 2, and Tier 3
5 Vaccine (Include COVID-19) Market Size by Type
  1. 5.1 Global Vaccine (Include COVID-19) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Vaccine (Include COVID-19) Revenue by Type (2021-2032)
  3. 5.3 Global Vaccine (Include COVID-19) Revenue Market Share by Type (2021-2032)
6 Vaccine (Include COVID-19) Market Size by Application
  1. 6.1 Global Vaccine (Include COVID-19) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Vaccine (Include COVID-19) Revenue by Application (2021-2032)
  3. 6.3 Global Vaccine (Include COVID-19) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Vaccine (Include COVID-19) Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck Vaccine (Include COVID-19) Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Vaccine (Include COVID-19) Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 GSK
  20. 7.4.1 GSK Company Information
  21. 7.4.2 GSK Business Overview
  22. 7.4.3 GSK Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GSK Vaccine (Include COVID-19) Product Portfolio
  24. 7.4.5 GSK Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Vaccine (Include COVID-19) Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Zhejiang Pukang
  32. 7.6.1 Zhejiang Pukang Company Information
  33. 7.6.2 Zhejiang Pukang Business Overview
  34. 7.6.3 Zhejiang Pukang Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Zhejiang Pukang Vaccine (Include COVID-19) Product Portfolio
  36. 7.6.5 Zhejiang Pukang Recent Developments
  37. 7.7 Walvax Biotechnology
  38. 7.7.1 Walvax Biotechnology Company Information
  39. 7.7.2 Walvax Biotechnology Business Overview
  40. 7.7.3 Walvax Biotechnology Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Walvax Biotechnology Vaccine (Include COVID-19) Product Portfolio
  42. 7.7.5 Walvax Biotechnology Recent Developments
  43. 7.8 Viatris
  44. 7.8.1 Viatris Company Information
  45. 7.8.2 Viatris Business Overview
  46. 7.8.3 Viatris Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Viatris Vaccine (Include COVID-19) Product Portfolio
  48. 7.8.5 Viatris Recent Developments
  49. 7.9 Sinovac
  50. 7.9.1 Sinovac Company Information
  51. 7.9.2 Sinovac Business Overview
  52. 7.9.3 Sinovac Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sinovac Vaccine (Include COVID-19) Product Portfolio
  54. 7.9.5 Sinovac Recent Developments
  55. 7.10 Sinovac
  56. 7.10.1 Sinovac Company Information
  57. 7.10.2 Sinovac Business Overview
  58. 7.10.3 Sinovac Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sinovac Vaccine (Include COVID-19) Product Portfolio
  60. 7.10.5 Sinovac Recent Developments
  61. 7.11 Serum Institute
  62. 7.11.1 Serum Institute Company Information
  63. 7.11.2 Serum Institute Business Overview
  64. 7.11.3 Serum Institute Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Serum Institute Vaccine (Include COVID-19) Product Portfolio
  66. 7.11.5 Serum Institute Recent Developments
  67. 7.12 Panacea Biotec Ltd
  68. 7.12.1 Panacea Biotec Ltd Company Information
  69. 7.12.2 Panacea Biotec Ltd Business Overview
  70. 7.12.3 Panacea Biotec Ltd Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Panacea Biotec Ltd Vaccine (Include COVID-19) Product Portfolio
  72. 7.12.5 Panacea Biotec Ltd Recent Developments
  73. 7.13 LG Life Sciences
  74. 7.13.1 LG Life Sciences Company Information
  75. 7.13.2 LG Life Sciences Business Overview
  76. 7.13.3 LG Life Sciences Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  77. 7.13.4 LG Life Sciences Vaccine (Include COVID-19) Product Portfolio
  78. 7.13.5 LG Life Sciences Recent Developments
  79. 7.14 KM Biologics
  80. 7.14.1 KM Biologics Company Information
  81. 7.14.2 KM Biologics Business Overview
  82. 7.14.3 KM Biologics Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  83. 7.14.4 KM Biologics Vaccine (Include COVID-19) Product Portfolio
  84. 7.14.5 KM Biologics Recent Developments
  85. 7.15 Hualan Bio
  86. 7.15.1 Hualan Bio Company Information
  87. 7.15.2 Hualan Bio Business Overview
  88. 7.15.3 Hualan Bio Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Hualan Bio Vaccine (Include COVID-19) Product Portfolio
  90. 7.15.5 Hualan Bio Recent Developments
  91. 7.16 Halfkin Bio-Pharmaceuticals
  92. 7.16.1 Halfkin Bio-Pharmaceuticals Company Information
  93. 7.16.2 Halfkin Bio-Pharmaceuticals Business Overview
  94. 7.16.3 Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Product Portfolio
  96. 7.16.5 Halfkin Bio-Pharmaceuticals Recent Developments
  97. 7.17 CSL
  98. 7.17.1 CSL Company Information
  99. 7.17.2 CSL Business Overview
  100. 7.17.3 CSL Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  101. 7.17.4 CSL Vaccine (Include COVID-19) Product Portfolio
  102. 7.17.5 CSL Recent Developments
  103. 7.18 Changchun Institute of Biological
  104. 7.18.1 Changchun Institute of Biological Company Information
  105. 7.18.2 Changchun Institute of Biological Business Overview
  106. 7.18.3 Changchun Institute of Biological Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Changchun Institute of Biological Vaccine (Include COVID-19) Product Portfolio
  108. 7.18.5 Changchun Institute of Biological Recent Developments
  109. 7.19 Bio-Med
  110. 7.19.1 Bio-Med Company Information
  111. 7.19.2 Bio-Med Business Overview
  112. 7.19.3 Bio-Med Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Bio-Med Vaccine (Include COVID-19) Product Portfolio
  114. 7.19.5 Bio-Med Recent Developments
  115. 7.20 Bharat Biotech
  116. 7.20.1 Bharat Biotech Company Information
  117. 7.20.2 Bharat Biotech Business Overview
  118. 7.20.3 Bharat Biotech Vaccine (Include COVID-19) Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Bharat Biotech Vaccine (Include COVID-19) Product Portfolio
  120. 7.20.5 Bharat Biotech Recent Developments
8 North America
  1. 8.1 North America Vaccine (Include COVID-19) Revenue (2021-2032)
  2. 8.2 North America Vaccine (Include COVID-19) Revenue by Type (2021-2032)
  3. 8.2.1 North America Vaccine (Include COVID-19) Revenue by Type (2021-2026)
  4. 8.2.2 North America Vaccine (Include COVID-19) Revenue by Type (2027-2032)
  5. 8.3 North America Vaccine (Include COVID-19) Revenue Share by Type (2021-2032)
  6. 8.4 North America Vaccine (Include COVID-19) Revenue by Application (2021-2032)
  7. 8.4.1 North America Vaccine (Include COVID-19) Revenue by Application (2021-2026)
  8. 8.4.2 North America Vaccine (Include COVID-19) Revenue by Application (2027-2032)
  9. 8.5 North America Vaccine (Include COVID-19) Revenue Share by Application (2021-2032)
  10. 8.6 North America Vaccine (Include COVID-19) Revenue by Country
  11. 8.6.1 North America Vaccine (Include COVID-19) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Vaccine (Include COVID-19) Revenue by Country (2021-2026)
  13. 8.6.3 North America Vaccine (Include COVID-19) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Vaccine (Include COVID-19) Revenue (2021-2032)
  2. 9.2 Europe Vaccine (Include COVID-19) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Vaccine (Include COVID-19) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Vaccine (Include COVID-19) Revenue by Type (2027-2032)
  5. 9.3 Europe Vaccine (Include COVID-19) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Vaccine (Include COVID-19) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Vaccine (Include COVID-19) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Vaccine (Include COVID-19) Revenue by Application (2027-2032)
  9. 9.5 Europe Vaccine (Include COVID-19) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Vaccine (Include COVID-19) Revenue by Country
  11. 9.6.1 Europe Vaccine (Include COVID-19) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Vaccine (Include COVID-19) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Vaccine (Include COVID-19) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Vaccine (Include COVID-19) Revenue (2021-2032)
  2. 10.2 China Vaccine (Include COVID-19) Revenue by Type (2021-2032)
  3. 10.2.1 China Vaccine (Include COVID-19) Revenue by Type (2021-2026)
  4. 10.2.2 China Vaccine (Include COVID-19) Revenue by Type (2027-2032)
  5. 10.3 China Vaccine (Include COVID-19) Revenue Share by Type (2021-2032)
  6. 10.4 China Vaccine (Include COVID-19) Revenue by Application (2021-2032)
  7. 10.4.1 China Vaccine (Include COVID-19) Revenue by Application (2021-2026)
  8. 10.4.2 China Vaccine (Include COVID-19) Revenue by Application (2027-2032)
  9. 10.5 China Vaccine (Include COVID-19) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Vaccine (Include COVID-19) Revenue (2021-2032)
  2. 11.2 Asia Vaccine (Include COVID-19) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Vaccine (Include COVID-19) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Vaccine (Include COVID-19) Revenue by Type (2027-2032)
  5. 11.3 Asia Vaccine (Include COVID-19) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Vaccine (Include COVID-19) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Vaccine (Include COVID-19) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Vaccine (Include COVID-19) Revenue by Application (2027-2032)
  9. 11.5 Asia Vaccine (Include COVID-19) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Vaccine (Include COVID-19) Revenue by Country
  11. 11.6.1 Asia Vaccine (Include COVID-19) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Vaccine (Include COVID-19) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Vaccine (Include COVID-19) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Vaccine (Include COVID-19) Revenue (2021-2032)
  2. 12.2 SAMEA Vaccine (Include COVID-19) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Vaccine (Include COVID-19) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Vaccine (Include COVID-19) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Vaccine (Include COVID-19) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Vaccine (Include COVID-19) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Vaccine (Include COVID-19) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Vaccine (Include COVID-19) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Vaccine (Include COVID-19) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Vaccine (Include COVID-19) Revenue by Country
  11. 12.6.1 SAMEA Vaccine (Include COVID-19) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Vaccine (Include COVID-19) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Vaccine (Include COVID-19) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst